Effect of a Probiotic-based Product on Blood Pressure
The Effect of a Probiotic-based Product on Blood Pressure and Other Known Risk Factors Linked to Cardiovascular Diseases.
1 other identifier
interventional
142
1 country
1
Brief Summary
The aim of the present study was to examine the efficacy of a probiotic-based product on either reducing hypertension or preventing a high normal blood pressure from reaching hypertensive levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2010
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 7, 2013
CompletedFirst Posted
Study publicly available on registry
November 21, 2013
CompletedNovember 21, 2013
November 1, 2013
8 months
November 7, 2013
November 14, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Changes from baseline in systolic and diastolic blood pressure after 3 months of probiotic intervention
Baseline, 3 months
Secondary Outcomes (1)
Changes from baseline of blood parameters, such as inflammatory markers and blood lipids, linked to increased risk for cardiovascular diseases
Baseline, 3 months
Other Outcomes (1)
Effect of study product on intestinal microbiota as analysed in fecal samples
Baseline, 3 months
Study Arms (3)
Fermented blueberry product
ACTIVE COMPARATORPlacebo
PLACEBO COMPARATORProbiotic bacteria
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Healthy individuals at the age of 40-75 years.
- Blood-pressure \>140/90 mmHg that has been confirmed at 2-3 separate occasions or represents the mean value of a 24-hour measurement.
- Triglycerides \>1,7 mmol/L and/or HDL \<1 mmol/L (men)/1,29 mmol/L (women).
- Fasting plasma glucose levels \>5,6 mmol/L and/or waist circumference \>102 cm (men)/88 cm (women).
- BMI \<40.
You may not qualify if:
- Medically treated allergy or allergy to any of the ingredients of the study product.
- Medication for high levels of blood lipids.
- Metabolic disease, such as type one diabetes.
- Confirmed diseases of the heart, liver of kidneys.
- Chronic inflammatory disease requiring medication.
- Pregnant or nursing.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Probi ABlead
Study Sites (1)
Unknown Facility
Malmo, Sweden
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2013
First Posted
November 21, 2013
Study Start
October 1, 2010
Primary Completion
June 1, 2011
Study Completion
June 1, 2011
Last Updated
November 21, 2013
Record last verified: 2013-11